Shares of COMPASS Pathways surged on Wednesday after the company announced the U.S. Food and Drug Administration (FDA) had accepted its application for breakthrough therapy designation for its psilocybin-based therapy, COMP360.
The FDA’s acceptance of the application signals a significant milestone for the London-based biotech, which has faced volatility amid clinical trial outcomes and regulatory scrutiny. COMPASS Pathways’ stock, listed under the ticker CMPS on the Nasdaq, jumped more than 20% in premarket trading following the announcement.
The breakthrough therapy designation, if granted, would accelerate the development and review process for COMP360, which is being evaluated for treatment-resistant depression. The designation is reserved for therapies that demonstrate substantial improvement over existing treatments for serious or life-threatening conditions.
COMPASS Pathways has emphasized the potential of psilocybin, the psychoactive compound in magic mushrooms, as a groundbreaking treatment for mental health disorders. The company’s phase IIb trial data, published in 2021, showed promising results, though subsequent analyses have prompted caution among investors.
The FDA’s decision to accept the application reflects growing interest in psychedelic therapies, despite ongoing debates about their efficacy and safety. Analysts note that regulatory approval could open a new frontier in mental health treatment, though hurdles remain.
COMPASS Pathways has not yet provided a timeline for the FDA’s decision on the breakthrough therapy designation. The company remains focused on advancing its clinical programs and expanding its research pipeline.
